Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial
Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. This is a randomized, do...
Saved in:
Published in | Clinical, cosmetic and investigational dermatology Vol. 9; pp. 325 - 332 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2016
Taylor & Francis Ltd Dove Medical Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.
This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi:
-zeaxanthin and
(
)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter
. The individual typological angle was calculated. Subjective assessments were also recorded.
Overall skin tone was significantly improved in the L/Zi group compared to placebo (
<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.
L/Zi supplementation lightens and improves skin conditions. |
---|---|
AbstractList | Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. Subjects and methods: This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18–45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II–IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded. Results: Overall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle. Conclusion: L/Zi supplementation lightens and improves skin conditions. Vijaya Juturu,1 James P Bowman,2 Jayant Deshpande1 1Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ, 2James P Bowman & Associates LLC, Loveland, OH, USA Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.Subjects and methods: This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10mg lutein (L) and 2mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded.Results: Overall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.Conclusion: L/Zi supplementation lightens and improves skin conditions. Keywords: lutein, zeaxanthin isomers, skin lightening, minimal erythemal dose, individual typological angle, overall skin tone Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: -zeaxanthin and ( )-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter . The individual typological angle was calculated. Subjective assessments were also recorded. Overall skin tone was significantly improved in the L/Zi group compared to placebo ( <0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle. L/Zi supplementation lightens and improves skin conditions. Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.PURPOSECarotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources. These carotenoids may be able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants.This is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded.SUBJECTS AND METHODSThis is a randomized, double-blind, placebo-controlled clinical trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were recruited and 46 subjects completed the study) (males and females, age: 18-45 years) with mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified as Fitzpatrick skin type II-IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®. The individual typological angle was calculated. Subjective assessments were also recorded.Overall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.RESULTSOverall skin tone was significantly improved in the L/Zi group compared to placebo (P<0.0237), and luminance (L*) values were significantly increased in the L/Zi group. Mean minimal erythemal dose was increased with L/Zi supplementation after 12 weeks of supplementation. L/Zi supplementation significantly increased the individual typological angle.L/Zi supplementation lightens and improves skin conditions.CONCLUSIONL/Zi supplementation lightens and improves skin conditions. |
Audience | Academic |
Author | Juturu, Vijaya Bowman, James Deshpande, Jayant |
AuthorAffiliation | 1 Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ 2 James P Bowman & Associates LLC, Loveland, OH, USA |
AuthorAffiliation_xml | – name: 1 Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ – name: 2 James P Bowman & Associates LLC, Loveland, OH, USA |
Author_xml | – sequence: 1 givenname: Vijaya surname: Juturu fullname: Juturu, Vijaya – sequence: 2 givenname: James surname: Bowman fullname: Bowman, James – sequence: 3 givenname: Jayant surname: Deshpande fullname: Deshpande, Jayant |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27785083$$D View this record in MEDLINE/PubMed |
BookMark | eNptkltvFCEUxyemxtbaN58NiYnxoVO5DjM-mDTrbZMmfVCfCQPMDpWBLTDr5fv4PWW7W9M2wgMczv_8wrk8rQ588KaqniN4hhHlbxaL5fuzLwgxhrpH1RFCvK05ROzgzv2wOknpCpZFOsZJ-6Q6xJy3DLbkqPpzuTFROgfSd-tBLnQgvb6xamdXYzbe-lVtp3UMm3IDZhiMygn8sHkEoYSCNK_XzkzGZ5lt8CAMwM3ZFNyW9NvIn9LnsZg2hcnE9BZIoMPcO1P3znp9CtZOKtOHWgWfY3DOaKCKx6pCz9FK96x6PEiXzMn-PK6-ffzwdfG5vrj8tFycX9SKwS7XUms19BL1irOeNlpzrBHuSWsIastumo6QnhDFYUnfwF4yCqHRLSJ40Lghx9Vyx9VBXol1tJOMv0SQVtw8hLgSMmarnBEQDVRTjgiFlHZ4kB2ThDDZ0UZSrGhhvdux1nM_Ga1KfUq17kHve7wdxSpsBIMNYR0qgNd7QAzXs0lZTDYp45z0JsxJoJYwRjCnbZG-fCC9CnP0pVQCY8waTrt2q3q1U61kSWA00uUxhdKr0rUkzhuIO8wZYkX44u7X__35dmyKAO8EKoaUohmEsrvul0ysEwiK7XiK7XiK_XiWoNMHQbfc_8r_Anvn55U |
CitedBy_id | crossref_primary_10_61873_YAOK3799 crossref_primary_10_1111_jocd_12747 crossref_primary_10_1007_s10811_024_03372_1 crossref_primary_10_1016_j_tifs_2021_10_017 crossref_primary_10_1111_jfpp_15260 crossref_primary_10_1016_j_fct_2021_112328 crossref_primary_10_3390_ijms25031431 crossref_primary_10_1016_j_plaphy_2022_09_034 crossref_primary_10_3390_ijms242015199 crossref_primary_10_1093_nutrit_nuz096 crossref_primary_10_3390_md22030131 crossref_primary_10_1016_j_chemosphere_2021_132932 crossref_primary_10_1016_j_tifs_2019_11_015 crossref_primary_10_3390_pharmaceutics14102160 crossref_primary_10_3892_br_2022_1545 crossref_primary_10_1007_s13671_020_00306_1 crossref_primary_10_4236_jcdsa_2020_104020 crossref_primary_10_1007_s44187_025_00287_9 crossref_primary_10_3892_br_2024_1742 crossref_primary_10_1016_j_jaad_2020_03_115 crossref_primary_10_3746_pnf_2021_26_4_425 crossref_primary_10_1007_s12634_018_5628_y crossref_primary_10_1007_s11274_023_03747_5 crossref_primary_10_3390_nu14061248 crossref_primary_10_3390_antiox8080259 crossref_primary_10_1016_j_psj_2021_101054 crossref_primary_10_1016_j_jff_2020_104265 crossref_primary_10_1007_s13659_022_00363_y crossref_primary_10_3390_cosmetics8030070 crossref_primary_10_1016_j_aqrep_2022_101388 crossref_primary_10_1007_s13555_018_0221_x crossref_primary_10_1016_j_ijbiomac_2024_133839 crossref_primary_10_3389_fvets_2022_906853 crossref_primary_10_3390_molecules27165334 crossref_primary_10_1111_azo_12488 crossref_primary_10_1111_jocd_13854 crossref_primary_10_1007_s13555_019_00345_y crossref_primary_10_1111_jocd_70017 crossref_primary_10_3390_foods12132516 crossref_primary_10_1002_jvc2_385 crossref_primary_10_7759_cureus_40892 crossref_primary_10_1016_j_nutres_2021_04_007 crossref_primary_10_3390_jcm12237488 crossref_primary_10_1111_php_13525 crossref_primary_10_3390_antiox10091448 crossref_primary_10_1007_s15011_018_2051_7 crossref_primary_10_3390_nu13010203 crossref_primary_10_1111_jocd_14137 crossref_primary_10_1155_2022_7881717 crossref_primary_10_3390_antiox10101511 crossref_primary_10_1111_phpp_12423 crossref_primary_10_1016_j_clindermatol_2021_05_007 crossref_primary_10_3390_cosmetics10050143 crossref_primary_10_3390_cosmetics10050142 crossref_primary_10_3390_scipharm88020027 crossref_primary_10_1016_j_phymed_2024_155508 crossref_primary_10_3390_life13051120 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2016 Dove Medical Press Limited 2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2016 Juturu et al. This work is published and licensed by Dove Medical Press Limited 2016 |
Copyright_xml | – notice: COPYRIGHT 2016 Dove Medical Press Limited – notice: 2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2016 Juturu et al. This work is published and licensed by Dove Medical Press Limited 2016 |
DBID | AAYXX CITATION NPM 3V. 7RV 7XB 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH KB0 M2O MBDVC NAPCQ PHGZM PHGZT PIMPY PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.2147/CCID.S115519 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database (NC LIVE) ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library Nursing & Allied Health Database (Alumni Edition) ProQuest Research Library (NC LIVE) Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1178-7015 |
EndPage | 332 |
ExternalDocumentID | oai_doaj_org_article_01f4d4713404492fa95a335a946a42c4 PMC5063591 A602927515 27785083 10_2147_CCID_S115519 |
Genre | Journal Article |
GroupedDBID | --- 0YH 29B 2WC 53G 5VS 7RV 8FI 8FJ 8G5 AAYXX ABUWG ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C1A CCPQU CITATION DIK DWQXO E3Z EBD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HYE IAO IHR IHW IPNFZ ITC KQ8 M2O M48 M~E NAPCQ O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RPM TDBHL TR2 TUS UKHRP VDV NPM 3V. 7XB 8FK MBDVC PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c509t-addcfba1bc75b46dd72d12b38e31818166933b33c70850e0ba5400ed8132fd263 |
IEDL.DBID | M48 |
ISSN | 1178-7015 |
IngestDate | Wed Aug 27 01:19:02 EDT 2025 Thu Aug 21 18:04:37 EDT 2025 Thu Jul 10 18:48:46 EDT 2025 Fri Jul 25 08:37:57 EDT 2025 Thu May 22 21:18:41 EDT 2025 Thu Jan 02 22:21:29 EST 2025 Thu Apr 24 23:05:08 EDT 2025 Tue Jul 01 01:55:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | zeaxanthin isomers overall skin tone individual typological angle minimal erythemal dose lutein skin lightening |
Language | English |
License | http://creativecommons.org/licenses/by-nc/3.0 The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c509t-addcfba1bc75b46dd72d12b38e31818166933b33c70850e0ba5400ed8132fd263 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/CCID.S115519 |
PMID | 27785083 |
PQID | 2225674988 |
PQPubID | 3933178 |
PageCount | 8 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_01f4d4713404492fa95a335a946a42c4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5063591 proquest_miscellaneous_1835532748 proquest_journals_2225674988 gale_healthsolutions_A602927515 pubmed_primary_27785083 crossref_citationtrail_10_2147_CCID_S115519 crossref_primary_10_2147_CCID_S115519 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand – name: Auckland |
PublicationTitle | Clinical, cosmetic and investigational dermatology |
PublicationTitleAlternate | Clin Cosmet Investig Dermatol |
PublicationYear | 2016 |
Publisher | Dove Medical Press Limited Taylor & Francis Ltd Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Taylor & Francis Ltd – name: Dove Medical Press |
References | 12880433 - J Invest Dermatol. 2003 Aug;121(2):399-405 23644932 - JAMA. 2013 May 15;309(19):2005-15 25741404 - Oxid Med Cell Longev. 2015;2015:579675 15949675 - Biochim Biophys Acta. 2005 May 30;1740(2):101-7 19122479 - Skin Pharmacol Physiol. 2009;22(1):31-44 17717424 - Skin Pharmacol Physiol. 2007;20(6):283-91 16556283 - J Dermatol. 2006 Feb;33(2):132-4 19168000 - Clin Dermatol. 2009 Mar-Apr;27(2):195-201 5696561 - Calif Med. 1968 Oct;109(4):319-20 7603884 - Nutr Cancer. 1995;23(3):233-46 8554331 - Arch Biochem Biophys. 1995 Dec 20;324(2):385-90 9478000 - Invest Ophthalmol Vis Sci. 1998 Feb;39(2):397-406 9651820 - J Dermatol Sci. 1998 Mar;16(3):226-30 16978905 - Int J Biochem Cell Biol. 2007;39(1):44-84 12239422 - Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):291-6 23605606 - Acta Med Iran. 2013 Apr 06;51(3):195-8 16400064 - Am J Clin Nutr. 2006 Jan;83(1):163-9 9828775 - Br J Ophthalmol. 1998 Aug;82(8):907-10 14585305 - Mol Aspects Med. 2003 Dec;24(6):345-51 17446716 - Skin Pharmacol Physiol. 2007;20(4):199-210 10609870 - Biofactors. 1999;10(2-3):105-13 18669545 - Br J Ophthalmol. 2008 Sep;92(9):1163-8 8127329 - N Engl J Med. 1994 Apr 14;330(15):1029-35 15009738 - J Invest Dermatol. 2004 Feb;122(2):510-7 24742502 - Ageing Res Rev. 2014 Jul;16:1-11 14513828 - Br J Nutr. 2003 Sep;90(3):487-502 12747216 - Int J Vitam Nutr Res. 2003 Mar;73(2):95-100 8602180 - N Engl J Med. 1996 May 2;334(18):1150-5 12514275 - J Nutr. 2003 Jan;133(1):98-101 15570017 - J Nutr. 2004 Dec;134(12):3225-32 18227626 - Ann Nutr Metab. 2007;51(6):571-3 17070769 - Biochim Biophys Acta. 2007 Jan;1768(1):167-74 18044138 - Clin Interv Aging. 2007;2(2):219-36 11444419 - J Am Coll Nutr. 2001 Jun;20(3):232-8 15189118 - Annu Rev Nutr. 2004;24:173-200 9675037 - Arch Biochem Biophys. 1998 Jul 15;355(2):271-4 17173569 - J Cosmet Dermatol. 2006 Mar;5(1):30-8 15068825 - Toxicol Lett. 2004 Apr 15;150(1):57-83 9886572 - Carcinogenesis. 1998 Dec;19(12):2159-62 17656988 - Indian J Dermatol Venereol Leprol. 2002 Nov-Dec;68(6):320-2 |
References_xml | – reference: 15189118 - Annu Rev Nutr. 2004;24:173-200 – reference: 15570017 - J Nutr. 2004 Dec;134(12):3225-32 – reference: 16978905 - Int J Biochem Cell Biol. 2007;39(1):44-84 – reference: 12747216 - Int J Vitam Nutr Res. 2003 Mar;73(2):95-100 – reference: 9478000 - Invest Ophthalmol Vis Sci. 1998 Feb;39(2):397-406 – reference: 7603884 - Nutr Cancer. 1995;23(3):233-46 – reference: 9651820 - J Dermatol Sci. 1998 Mar;16(3):226-30 – reference: 16556283 - J Dermatol. 2006 Feb;33(2):132-4 – reference: 8554331 - Arch Biochem Biophys. 1995 Dec 20;324(2):385-90 – reference: 14513828 - Br J Nutr. 2003 Sep;90(3):487-502 – reference: 8602180 - N Engl J Med. 1996 May 2;334(18):1150-5 – reference: 9828775 - Br J Ophthalmol. 1998 Aug;82(8):907-10 – reference: 17446716 - Skin Pharmacol Physiol. 2007;20(4):199-210 – reference: 23644932 - JAMA. 2013 May 15;309(19):2005-15 – reference: 17717424 - Skin Pharmacol Physiol. 2007;20(6):283-91 – reference: 17173569 - J Cosmet Dermatol. 2006 Mar;5(1):30-8 – reference: 12880433 - J Invest Dermatol. 2003 Aug;121(2):399-405 – reference: 12239422 - Skin Pharmacol Appl Skin Physiol. 2002 Sep-Oct;15(5):291-6 – reference: 15068825 - Toxicol Lett. 2004 Apr 15;150(1):57-83 – reference: 15949675 - Biochim Biophys Acta. 2005 May 30;1740(2):101-7 – reference: 19168000 - Clin Dermatol. 2009 Mar-Apr;27(2):195-201 – reference: 25741404 - Oxid Med Cell Longev. 2015;2015:579675 – reference: 11444419 - J Am Coll Nutr. 2001 Jun;20(3):232-8 – reference: 18669545 - Br J Ophthalmol. 2008 Sep;92(9):1163-8 – reference: 12514275 - J Nutr. 2003 Jan;133(1):98-101 – reference: 9675037 - Arch Biochem Biophys. 1998 Jul 15;355(2):271-4 – reference: 16400064 - Am J Clin Nutr. 2006 Jan;83(1):163-9 – reference: 10609870 - Biofactors. 1999;10(2-3):105-13 – reference: 23605606 - Acta Med Iran. 2013 Apr 06;51(3):195-8 – reference: 24742502 - Ageing Res Rev. 2014 Jul;16:1-11 – reference: 18227626 - Ann Nutr Metab. 2007;51(6):571-3 – reference: 18044138 - Clin Interv Aging. 2007;2(2):219-36 – reference: 19122479 - Skin Pharmacol Physiol. 2009;22(1):31-44 – reference: 5696561 - Calif Med. 1968 Oct;109(4):319-20 – reference: 17656988 - Indian J Dermatol Venereol Leprol. 2002 Nov-Dec;68(6):320-2 – reference: 14585305 - Mol Aspects Med. 2003 Dec;24(6):345-51 – reference: 17070769 - Biochim Biophys Acta. 2007 Jan;1768(1):167-74 – reference: 8127329 - N Engl J Med. 1994 Apr 14;330(15):1029-35 – reference: 9886572 - Carcinogenesis. 1998 Dec;19(12):2159-62 – reference: 15009738 - J Invest Dermatol. 2004 Feb;122(2):510-7 |
SSID | ssj0000395738 |
Score | 2.3053322 |
Snippet | Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy sources.... Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and protect skin from environmental factors including high-energy... Vijaya Juturu,1 James P Bowman,2 Jayant Deshpande1 1Department of Scientific and Clinical Affairs, OmniActive Health Technologies Inc., Morristown, NJ, 2James... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 325 |
SubjectTerms | Acne Antioxidants Antioxidants (Nutrients) Cancer Carotenoids Clinical trials Diet Disease Double-blind studies Energy resources Family medical history Fibroblasts Free radicals Fruits Individual Typological Angle (ITA) Inflammation Lipids Lutein Minimal Erythemal Dose (MED) Nutrition research Original Research Overall Skin Tone Oxidative stress Skin Skin care Skin Lightening Ultraviolet radiation Vegetables Zeaxanthin Isomers (L/Zi) |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yB_EifltdNYKeNG7bJE3jbX26rMLqxYW9haRJ2YelFfueiP-P_6czaV55RcSLx7ahNJ1fJr_5yAwhzyrbitbZgimf10xUZcNcaDlTVoYKEBVEixHds4_V6bn4cCEv9lp9YU7YVB54-nFHedEKL_DEYy6ELlurpeVcWi0qK8omVgKFPW_PmIo6GMNPsY11UYCZpGDTm7LesS3P0Wr1_u0rWMfAFvRiP4pl-_9Uznu70zJzcm8rOrlBricOSY-nb79JroT-Frl6lqLkt8mvT9_R09TR8cu6p1htm9rexyvWoTEe0BnC1jt_Ak1JHRSdshSP7NMRm31OieUoOTq0FCAa4HX4pp_B_gCJXMLlehzQ8_2aWuqHresCc0Bc_Usak73cwFIufBc83Z3CpLFVyB1yfvLu8-qUpXYMrAFWsWGgCRsUq2uUdKLyXpW-KB2v0Y1aYPxRc-44bxSWwQu5s8AG8-BrMHhbX1b8LjnoYcr3CW0AIcFLrS0axby1bQ3EMrg8OC99sBl5sROKaVKtcmyZ0RmwWVCEBkVokggz8nwe_XWq0fGXcW9QvvMYrKwdbwDeTMKb-RfeMvIE0WGmY6qzfjDHVV7qUgE9zMjhDjgmKYTRoFldKaHrOiNP58ewlDE-Y_swbEcD2lVKDn8ExtybcDZ_a6lUjZX7M6IWCFxMZvmkX1_GcuESWKjUxYP_MfuH5BowxuSDOiQHm2_b8AhY2cY9jgvwNyDaNX4 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiHdDCxgJTmCaxHYeXFC7tCpILQhRqTfLjm26IkraZhch_g__k5nECV0hODqxoiQzHn_zzXiGkOeZ9sIbnbDcxgUTWVox4zxnuZYuA41ywmNE9-g4OzwRH07laSDcupBWOdrE3lDbtkKOfAf9kiwXZVG8Pb9g2DUKo6uhhcZ1sgEmuChmZGNv__jT54lliTEMxYsh4x1b8uzM5-_fvYY1DEihXNuL-pL9fxvmKzvTetbklW3o4Da5FfAj3R0Efodcc81dcuMoRMjvkV8fvyPLVNPu26KhWGmb6sb2I1ajI-6QCGGLkUugIaGDIiFL8bg-7bDR55BUjlKjraegng4eh0_66fQPkMYZDBddi6z3G6qpbVemdswAaLWvaJ_oZVoW8uBrZ-l4ApP2bULuk5OD_S_zQxZaMbAKEMWSgRWsUKSmyqURmbV5apPU8AIp1ARjjyXnhvMqxxJ4LjYakGDsbAHOrrdpxh-QWQOfvEloBdrhrCxLjQ4x99oXACqdiZ2x0jodkZejUFQV6pRju4xagb-CIlQoQhVEGJEX0-zzoT7HP-btoXynOVhVu7_QXn5VYZGqOPHCCjxdGwtRpl6XUnMudSkyLdJKROQpaocajqhOtkHtZnFapjlAw4hsj4qjgjHo1B_Vjciz6TYsY4zN6Ma1q06BZZWSwx-BOQ8HPZveNc3zAqv2RyRf08C1j1m_0yzO-lLhEhCoLJNH_3-tLXITcGBglrbJbHm5co8Bay3Nk7CgfgOI7y4c priority: 102 providerName: ProQuest |
Title | Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial |
URI | https://www.ncbi.nlm.nih.gov/pubmed/27785083 https://www.proquest.com/docview/2225674988 https://www.proquest.com/docview/1835532748 https://pubmed.ncbi.nlm.nih.gov/PMC5063591 https://doaj.org/article/01f4d4713404492fa95a335a946a42c4 |
Volume | 9 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1bi9QwFA57AfFFvFtdxwj6pFl7SZpWENkddxmFWUUcWJ9C0qTuYGl1OiOr_8f_6TltOuywio9tQ2h7bt-55BxCnqS65KXREZM2zBhP44IZVyZMauFS4CjHS8zoTk_SyYy_OxWnW2SYNup_YPtX1w7nSc0W1f7595-vQeBfYRlzxOWL8fjtm30QSzD--TbZBZskcZbB1AP9TidjOqobax1F4DZJMIJ9FfylDTbsU9fG_7KyvmCtNispL5im4-vkmseU9KBnghtky9U3yZWpz5rfIr_f_8DIU0Xbr_OaYvdtqmvbXbEKnXOHwRE2H-IL1Bd5UAzSUjzCT1sc_tkXmiMlaVNSYFkH2-FOv5w-BwqdweW8bTAS_pJqapuVqRwzAGTtc9oVf5mG-dr4ylk6nMqk3eiQ22R2fPRpPGF-PAMrAGUsGWjGAslsCikMT62VsY1ik2QYVo0wH5kniUmSQmJbPBcaDegwdDYDB7i0cZrcITs1fPI9QgvgGGdFnmt0kpNSlxkATWdCZ6ywTgfk2UAUVfje5ThCo1LgwyAJFZJQeRIG5Ol69be-Z8c_1h0ifddrsNN2d6NZfFFecFUYldxyPHEbcp7Hpc6FThKhc55qHhc8II-QO1R_bHWtL9RBGsZ5LAEuBmRvYBw18LdCNzuVPM-ygDxePwbRxnyNrl2zahVoWyES-COw5m7PZ-t3jaXMsJN_QOQGB258zOaTen7WtQ8XgEpFHt3_74s_IFcBHvqA0x7ZWS5W7iFAsKUZke3w82REdg-PTj58HHWBjFEncX8AJvU1Pg |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELZKKgEXxJuFQo1ET-B2Y3tfSAi1aauENgGhVurN2GsvjYh2Szfh9X-48huZ2ReNENx63KxleTPfvMczhDwLdSYzo_sssn7MZMhTZlwmWKQDFwKinMwwozuehMNj-eYkOFkhv9q7MFhW2crESlDbIsUY-Rb6JWEkkzh-ffaZ4dQozK62IzRqWBy471_BZStfjXaBvhuc7-8dDYasmSrAUlCOcwYMneLpTBoFRobWRtz2uRExRgP7mEYDH98IkUbYzc35RoNR4zsbg9-WWR4K2PcKWZUi9HmPrO7sTd6976I6Pqa9RFxX2OMIoK3BYLS7CTIDLJNkSfdVIwL-VgQXNOFyleYFtbd_k9xo7FW6XQPsFllx-W1yddxk5O-Qn2-_YFRrRstP05xiZ2-qc1s9sRk6_g4DL2zaxi5oU0BCMQBMsT0ALXGwaF3EjiihRUaBHRxshzv9cPobUP8UHqdlgVH2l1RTWyzMzDEDRrJ9QavCMlOwpu5-5ixtb3zSaizJXXJ8KUS6R3o5fPIDQlNAo7NBkmh0wEWmsxiMWGd8Z2xgnfbI85YoKm36ouN4jpkC_whJqJCEqiGhRza61Wd1P5B_rNtB-nZrsIt39UNx_lE1QkH5_Uxaibd5fSkTnukk0EIEOpGhljyVHllHdKj6Smwni9Q2QC_hEZiiHllrgaMa4VOqP6zikafdaxAbmAvSuSsWpQJJHgQC_hFYc7_GWXdWHkUxTgnwSLSEwKWPWX6TT0-r1uQBWLxB0n_4_2Otk2vDo_GhOhxNDh6R62CDNlGtNdKbny_cY7Dz5uZJw1yUfLhsfv4NSbNqhw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ028IO5kDGYk9gRmaWLngoTQ1q5aGSsTYtLejB07rFqVjKXl9n_4E_w6zkmcsArB2x7TWJbT85378TmEPI1UznOt-iw2fsJ4FGRM2zxksRI2AkRZnmNG93AS7R_zNyfiZIX8au_CYFllKxNrQW3KDGPk2-iXRDFPwWHLXVnE0XD0-vwzwwlSmGltx2k0EDmw37-C-1a9Gg-B1ltBMNr7MNhnbsIAy0BRzhkwd4Yn1VksNI-MiQPTD3SYYGSwjyk18Pd1GGYxdnazvlZg4PjWJODD5SaIQtj3GlmN0SvqkdXdvcnR-y7C42MKLEyaanscB7Q9GIyHL0B-gJWSLunBelzA30rhklZcrti8pAJHN8kNZ7vSnQZst8iKLW6TtUOXnb9Dfr77ghGuGa3OpgXFLt9UFaZ-YjMMAlgMwrBpG8egrpiEYjCYYqsAWuGQ0aagHRFDy5wCa1jYDnf6YdU3QMIpPE6rEiPuL6miplzomWUaDGbznNZFZrpkrgZ_Zg1tb3_SekTJXXJ8JUS6R3oFfPIDQjNApjUiTRU642Gu8gQMWqt9q40wVnnkWUsUmbke6TiqYybBV0ISSiShdCT0yFa3-rzpDfKPdbtI324NdvSufygvPkknIKTfz7nheLPX5zwNcpUKFYZCpTxSPMi4RzYRHbK5HtvJJbkT-UEaxGCWemSjBY50gqiSf9jGI0-61yBCMC-kClsuKglSXYgQ_hFYc7_BWXfWII4TnBjgkXgJgUsfs_ymmJ7WbcoFWL8i7a___1ibZA34WL4dTw4ekutgjroA1wbpzS8W9hGYfHP92PEWJR-vmp1_A_xwbrw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overall+skin+tone+and+skin-lightening-improving+effects+with+oral+supplementation+of+lutein+and+zeaxanthin+isomers%3A+a+double-blind%2C+placebo-controlled+clinical+trial&rft.jtitle=Clinical%2C+cosmetic+and+investigational+dermatology&rft.au=Juturu%2C+Vijaya&rft.au=Bowman%2C+James+P&rft.au=Deshpande%2C+Jayant&rft.date=2016-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-7015&rft.eissn=1178-7015&rft.volume=9&rft.spage=325&rft_id=info:doi/10.2147%2FCCID.S115519&rft.externalDBID=n%2Fa&rft.externalDocID=A602927515 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-7015&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-7015&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-7015&client=summon |